Hims And Hers Health Inc Revenue Growth Rates (HIMS), Current and Historic Growth - CSIMarket
CSIMarket
 


Hims and Hers Health Inc   (NYSE: HIMS)
    Sector  Healthcare    Industry Healthcare Facilities
   Industry Healthcare Facilities
   Sector  Healthcare
 

HIMS's Revenue Growth by Quarter and Year

Hims And Hers Health Inc 's Revenue results by quarter and year




HIMS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 753.21
1st Quarter March 607.79
FY 1,361.00

HIMSs Annual Revenue
Hims And Hers Health Inc 's Revenue in the fiscal year 2025 $ 2,347.38 millions
Hims And Hers Health Inc 's Revenue in the fiscal year 2024 $ 1,476.14 millions
Hims And Hers Health Inc 's Revenue in the fiscal year 2023 $ 871.95 millions
Hims And Hers Health Inc 's Revenue in the fiscal year 2022 $ 526.92 millions
Hims And Hers Health Inc 's Revenue in the fiscal year 2021 $ 271.88 millions




HIMS Revenue second quarter 2026 Y/Y Growth Comment
Hims and Hers Health Inc reported Revenue improvement of 38.41% year on year in the second quarter 2026, to $ 753.21 millions, this is lower than Hims And Hers Health Inc 's recent average Revenue rise of 70.37%.

Among companies who have reported second quarter 2026 results in the Healthcare Facilities industry only one Company has achieved higher year on year Revenue results in the second quarter 2026. While Hims And Hers Health Inc ' s Revenue rise of 38.41% ranks overall at the positon no. 590 in the second quarter 2026.




HIMS Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter December - 28.64 % 94.4 % 48.15 %
3rd Quarter September - 49.18 % 77.14 % 56.25 %
2nd Quarter June 38.41 % 72.43 % 52.35 % 82.42 %
1st Quarter March 3.77 % 110.6 % 45.78 % 88.3 %
FY   - 59.02 % 69.29 % -

Financial Statements
Hims And Hers Health Inc 's second quarter 2026 Revenue $ 753.21 millions HIMS's Income Statement
Hims And Hers Health Inc 's second quarter 2025 Revenue $ 544.20 millions Quarterly HIMS's Income Statement


HIMS Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter December - 3.57 % 20.12 % 9.46 %
3rd Quarter September - 9.9 % 27.02 % 9.24 %
2nd Quarter June 23.93 % -7.08 % 13.49 % 8.59 %
1st Quarter March -1.88 % 21.63 % 12.27 % 14.1 %
FY (Year on Year)   - 59.02 % 69.29 % -




Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #2
Healthcare Sector #142
Overall #590

Revenue Y/Y Growth Statistics
High Average Low
110.61 % 70.37 % 3.77 %
(Dec 31 2022)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #2
Healthcare Sector #142
Overall #590
Revenue Y/Y Growth Statistics
High Average Low
110.61 % 70.37 % 3.77 %
(Dec 31 2022)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Hims And Hers Health Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
27.54 % 13.88 % -7.08 %
(Sep 30 2022)  


HIMS's II. Quarter Q/Q Revenue Comment
Hims and Hers Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.93%, to $ 753.21 millions, from $607.79 millions in the first quarter.
HIMS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Hims And Hers Health Inc 's Revenue growth quarter on quarter, overall rank is 464.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #96
Overall #464
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #96
Overall #464
Revenue Q/Q Growth Statistics
High Average Low
27.54 % 13.88 % -7.08 %
(Sep 30 2022)  


HIMS's II. Quarter Q/Q Revenue Comment
Hims and Hers Health Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.93%, to $ 753.21 millions, from $607.79 millions in the first quarter.
HIMS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Hims And Hers Health Inc 's Revenue growth quarter on quarter, overall rank is 464.


Hims And Hers Health Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending
(Mar 31 2026)
12 Months Ending
(Dec 31 2025)
12 Months Ending
(Sep 30 2025)
12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2,578.49 $ 2,369.48 $ 2,347.38 $ 2,209.48 $ 2,012.31
Y / Y Revenue Growth (TTM) 28.14 % 32.84 % 59.02 % 77.85 % 88.47 %
Year on Year Revenue Growth Overall Ranking # 158 # 138 # 32 # 110 # 205
Seqeuential Revenue Change (TTM) 8.82 % 0.94 % 6.24 % 9.8 % 12.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 1165 # 734 # 186 # 512 # 997


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Hims And Hers Health Inc 's cumulative twelve months Revenue were $ 2,578 millions, company would post below average annual Revenue growth of 12.81% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Hims And Hers Health Inc 's Revenue growth from the 607.79% growth in Mar 31 2026.

In the Healthcare sector 51 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 138 to 158.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 9
Healthcare Sector # 52
Overall # 158

Revenue TTM Y/Y Growth Statistics
High Average Low
93.81 %
68.26 %
28.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 218
S&P 500 # 1165
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Hims And Hers Health Inc 's cumulative twelve months Revenue were $ 2,578 millions, company would post below average annual Revenue growth of 28.14% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Hims And Hers Health Inc 's Revenue growth from the 607.79% growth in Mar 31 2026.

In the Healthcare sector 51 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 138 to 158.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 9
Healthcare Sector # 52
Overall # 158

Revenue TTM Y/Y Growth Statistics
High Average Low
93.81 %
68.26 %
28.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 218
S&P 500 # 1165




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HIMS's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions


About Hims And Hers Health Inc Revenue Growth Rates (HIMS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Hims and Hers Health Inc (CIK 1773751).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001773751-26-000163
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Hims and Hers Health Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.